Procurement Summary: Semaglutide (SEMA-RES-001)

Section 1: Compound Identification and Procurement Data

This document provides a concise summary of Semaglutide (Catalog ID: SEMA-RES-001) for procurement and technical review purposes.

Field

Detail

Catalog ID

SEMA-RES-001

Compound Name

Semaglutide (GLP-1 Analogue)

Primary Focus

Research-grade synthetic peptide for metabolic studies.

Supplier/Manufacturer

[Supplier Name Placeholder]

Date of Summary

Date

Section 2: Compound Overview and Mechanism of Action

Semaglutide is a long-acting synthetic GLP-1 (Glucagon-like peptide-1) receptor agonist. It is a critical research tool used to investigate the physiological and pharmacological effects of GLP-1 signaling.

Structural Modifications for Enhanced Efficacy

The molecule is distinguished by two primary modifications designed to prolong its half-life and improve bioavailability:

1. C18 Fatty Acid Chain: This modification allows for high-affinity binding to serum albumin, which protects the peptide from renal clearance and degradation, enabling once-weekly dosing in clinical applications.
2. Aib Substitution: The amino acid Alanine has been substituted with alpha-Aminoisobutyric acid (Aib) in the GLP-1 backbone. This substitution confers high resistance to degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), further extending its effective half-life.

Research Applications

Semaglutide is widely used in research protocols focusing on:

• Obesity and appetite regulation.
• The pathophysiology of Type 2 Diabetes Mellitus (T2DM).
• Cardiovascular health and risk factor mitigation in metabolic syndrome.
• Neurobiological effects of GLP-1 analogues.

Section 3: Physical and Chemical Specifications

The following table details the required specifications for SEMA-RES-001 to ensure suitability for high-precision research and analytical applications.

Specification

Value

Procurement Check

Form

White Lyophilized Powder

[Pass/Fail Placeholder]

Purity (HPLC)

>99%

[Lot Specific Purity Placeholder]

Sequence

Modified GLP-1 backbone

[Conformity Check Placeholder]

Appearance

Homogenous, free from visible contaminants

[Inspection Result Placeholder]

Molecular Weight

[Placeholder for MW] Da

[Verification Placeholder]

Solubility

Typically soluble in water or dilute acetic acid

[Tested Placeholder]

Section 4: Storage, Handling, and Stability

Appropriate storage is critical to maintaining the activity and purity of the peptide.

Storage Conditions

State

Recommended Temperature

Notes

Lyophilized (as shipped)

Store at -20°C

Protect from light and moisture. Stable for Date months.

In Solution (Reconstituted)

Store at 2-8°C or -20°C (aliquots)

Minimize freeze-thaw cycles. Use within Date days/weeks.

Handling Requirements

• Handling Environment: Use a clean, controlled environment. Weighing and reconstitution should be performed in an ISO-certified clean bench if possible.
• Reconstitution Solvent: It is recommended to reconstitute the powder using sterile, high-purity water or an appropriate buffered solution (e.g., PBS).

Section 5: Quality Assurance Documentation Requirements

To ensure compliance and traceability, the following documentation is required for all shipments of SEMA-RES-001:

• Certificate of Analysis (CoA)
• Mass Spectrometry (MS) Report
• High-Performance Liquid Chromatography (HPLC) Report (Purity >99% required)
• Material Safety Data Sheet (MSDS) / Safety Data Sheet (SDS)

All required documents must be supplied as a digital file, linked below: File

Section 6: Safety and Regulatory Compliance

WARNING: Semaglutide (SEMA-RES-001) is a bioactive peptide intended for Research Use Only (RUO). It is NOT approved for human therapeutic or diagnostic use.

Safety Protocol Requirements

Buyer assumes all responsibility for safe handling, use, and proper disposal of the compound. All personnel working with SEMA-RES-001 must adhere to established laboratory safety protocols, including:

• Wearing appropriate Personal Protective Equipment (PPE), including lab coats, safety glasses, and chemical-resistant gloves.
• Working in a well-ventilated area.
• Establishing clear Standard Operating Procedures (SOPs) for spill containment and cleanup.

Disposal

Disposal must comply with all local, state, and national regulations for chemical and biological waste. In general, bioactive peptides should be chemically inactivated or incinerated. Consult the provided SDS for specific disposal instructions.

Section 7: Procurement Logistics and Timeline

The following outlines the required procurement steps and timeline for SEMA-RES-001.

Milestone

Target Date

Responsible Party

Status

Purchase Order Submission

Date

Person (Procurement)

[Placeholder]

Supplier Acknowledgment

Date

[Supplier Name Placeholder]

[Placeholder]

Estimated Ship Date (EXW)

Date

[Supplier Name Placeholder]

[Placeholder]

Expected Delivery Date

Date

Logistics Team

[Placeholder]

Material QC Check Completed

Date

QC Department

[Placeholder]

Section 8: Pricing and Quotation Summary

This section summarizes the most recent quotation for SEMA-RES-001.

Unit Size (mg)

Unit Cost (USD)

Quantity

Total Cost (USD)

5 mg

[Placeholder for Cost]

10

[Placeholder for Total]

10 mg

[Placeholder for Cost]

5

[Placeholder for Total]

Subtotal

[Total Subtotal Placeholder]

Shipping/Handling (Cold Chain)

[Shipping Cost Placeholder]

Total Procurement Cost

[Final Cost Placeholder]

Quotation Reference: [Quotation ID Placeholder]

Section 9: Supplier Contact Information

Please direct all procurement-related inquiries to the following contact:

Role

Contact Name

Contact Email

Contact Phone

Procurement Manager

Person

[Email Address Placeholder]

[Phone Number Placeholder]

Technical Support

[Technical Contact Placeholder]

[Tech Email Placeholder]

[Tech Phone Placeholder]

Section 10: Review and Approval

This summary has been reviewed and approved by the necessary internal departments.

Approvals

Department

Reviewer

Approval Date

Signature

Procurement

Person

Date

[Signature Placeholder]

Research & Development

Person

Date

[Signature Placeholder]

Quality Control

Person

Date

[Signature Placeholder]

This purchase order is contingent on the supplier's capacity to ship SEMA-RES-001 under verifiable cold chain conditions to the receiving location at Place.

Section 11: Document Revision History

Revision Number

Date

Description of Change

1.0

Date

Initial release of Procurement Summary.

1.1

Date

Updated pricing from new quotation.

1.2

Date

Confirmed storage protocols.

Section 12: Future Monitoring and Usage

The usage of this compound will be tracked against established research goals. The initial event for tracking compound stability and usage is the Material Receipt and Inspection Calendar event.

End of Procurement Summary Document